Ramelteon is a synthetic melatonin analogue working by binding to and activating melatonin receptors 1 and 2.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Ramelteon, a potent and highly selective MT1/MT2 receptor agonist with Ki values of 14 and 112 pM respectively, is orally active and has potential for insomnia research. It consistently lowers the time it takes to fall asleep over prolonged use without causing any residual effects the next morning, or symptoms of rebound insomnia or withdrawal after stopping[1].[2]. |
体内研究 | Ramelteon (administered orally; 0.1 and 1 mg/kg) effectively speeds up the adjustment of activity rhythms to new light-dark cycles in running wheel tests[3]. Ramelteon (administered orally; 3, 10, and 30 mg/kg) does not impair learning or memory as evidenced by performance in water maze tasks and the delayed match to position tasks in rats, suggesting no abuse potential for MT1/MT2 receptor agonists[3]. Ramelteon (administered orally at doses of 0.0001, 0.001, 0.01, and 0.1 mg/kg every 8 hours) markedly reduces wakefulness at doses of 0.001, 0.01, and 0.1 mg/kg, enhances slow-wave sleep at the same doses, and boosts rapid eye movement sleep at 0.1 mg/kg[4]. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00642694 | - | Terminated(Enrollment disconti... 展开 >>nued based on mutually agreed upon decision by PI and funding sponsor) 收起 << | - | - | |
NCT02969343 | Central Line-Associated Bloods... 展开 >>tream Infection (CLABSI) Venous Thromboembolism Patient Fall Catheter-Associated Infection Severe Hypoglycemia Opioid-Related Severe Adverse Drug Event Hospital Acquired Pressure Ulcer Adverse Drug Event Severe Hospital Acquired Delerium Rapid Response Related to Arrhythmia 收起 << | Not Applicable | Recruiting | September 2018 | United States, Massachusetts ... 展开 >> Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Alexandra C Businger 617-732-7063 abusinger@partners.org Contact: Patricia Dykes, RN PhD 617-732-8925 pdykes@partners.org Principal Investigator: David W Bates, MD MSc 收起 << |
NCT00893269 | Marijuana Dependence | Phase 1 | Completed | - | United States, Maryland ... 展开 >> Johns Hopkins University Baltimore, Maryland, United States, 21224 收起 << |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.86mL 0.77mL 0.39mL |
19.28mL 3.86mL 1.93mL |
38.56mL 7.71mL 3.86mL |
CAS号 | 196597-26-9 |
分子式 | C16H21NO2 |
分子量 | 259.343 |
别名 | TAK-375 |
运输 | 蓝冰 |
存储条件 |
粉末 Sealed in dry,Store in freezer, under -20°C 液体 -20°C:3-6个月-80°C:12个月 |
溶解度 |
DMSO: 50 mg/mL(192.79 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |
IP 2% DMSO+2% Tween80+40% PEG300+water 6 mg/mL clear PO 0.5% CMC-Na 30 mg/mL suspension |